Date:2/28/2011

Adjusted Diluted Earnings Per Share Guidance for 2011Year EndingDecember 31, 2011Projected GAAP diluted income per common share$2.43To$2.53Upfront and milestone-related payments to partners

$0.35$0.35Amortization of commercial intangible assets and inventory step-up

$1.33$1.33Acquisition and integration costs related to recent acquisitions.

$0.26$0.26Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus

$0.16$0.16Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of recent acquisitions

($0.33)($0.33)Diluted adjusted income per common share guidance $4.20To$4.30The company's guidance is being issued based on certain assumptions including:

Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results.

Includes all completed business development transactions as of February 28, 2011.

About Endo Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit www.endo.com.

(Tables Attached)The following tables present Endo's unaudited Total Revenues for the three months ended December 31, 201
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
2. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
3. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
4. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
7. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
9. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
10. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
11. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant